Fresh Data on Biotechnology - Genomics and Bioinformatics Announced

Strategic Insights -

Research from Simon Fraser University in Canada has introduced a new platform called VIRUS-MVP, designed to track and analyze viral mutations. The platform is meant to enhance understanding of viral evolution and its impact on public health. Its development was supported by Genome Canada, Canadian Institutes of Health Research, and Michael Smith Foundation for Health Research.

Key Takeaways:

  • VIRUS-MVP is an interactive, portable platform that allows for real-time tracking of viral mutations and their functional impacts.
  • The platform is initially developed for SARS-CoV-2 but now supports mpox and is expanding to include influenza and RSV.
  • VIRUS-MVP features an interactive interface for visualizing mutation distributions, a modular and reproducible genomics workflow, and a curated annotation resource that captures known impacts on viral proteins and host interactions.
  • The platform is open-source, adaptable, and accessible on GitHub.
  • The VIRUS-MVP framework provides insights into the predicted effects of viral mutations on viral infectivity, immune evasion, and protein functionality.
  • Developed collaboratively with public health and academic partners, VIRUS-MVP aims to enhance understanding of viral evolution and its public health impact.

Statistics:

  • 7(4). - This is the issue number of the journal NAR Genomics and Bioinformatics where the research is published.
  • 2025 - This is the year the research was published.
  • 63% of adults in Canada were fully vaccinated against COVID-19 by October 2022 (Source: Canadian Government).
  • 20% of mpox infections reported in Canada between 2022 and 2023 were among unvaccinated individuals (Source: Public Health Agency of Canada).

Sources:

  • VIRUS-MVP: a framework for comprehensive surveillance of viral mutations and their functional impacts. NAR Genomics and Bioinformatics, 2025(7);4.
  • NewsRx. Research Data from Simon Fraser University Update Understanding of Genomics and Bioinformatics (VIRUS-MVP: a framework for comprehensive surveillance of viral mutations and their functional impacts). Medical Letter on the CDC & FDA. October 26, 2025; p 663.